Which cancer types is erdafitinib suitable for?

As the world's first FGFR (fibroblast growth factor receptor) inhibitor approved for marketing, Erdafitinib marks an important step in molecular target-oriented precision tumor treatment. It is currently mainly used to treat locally advanced or metastatic urothelial cancer (mainly bladder cancer) with FGFR2 or FGFR3 mutations, especially for patients whose disease has progressed after previous platinum-containing chemotherapy, providing a new treatment option. Urothelial carcinoma is one of the most common malignant tumors in the urinary system, and approximately 15%-20% of such patients have FGFR gene abnormalities, making them the core target group for erdafitinib treatment.

In addition to bladder cancer, erdafitinib has also shown potential application value in other solid tumors. For example, in some cholangiocarcinomas, lung cancers and hepatocellular carcinomas, researchers are exploring its efficacy in patients with FGFR-related mutations. Although these indications have not yet been formally approved, relevant clinical research is advancing globally. Especially in patients who lack standard treatment options or have strong drug resistance, FGFR-targeting drugs may bring about a turnaround. In the future, erdafitinib is expected to further expand its indications to a wider range of FGFR variant solid tumors, bringing new growth points to precision medicine.

It should be noted that the use of erdafitinib requires clear genetic screening. Only when activating mutations or fusions of FGFR2 or FGFR3 are detected in the patient's tumor tissue or circulating tumor DNA can it be determined whether the drug is suitable for use. Since this treatment strategy relies heavily on molecular-level diagnosis, accurate detection is decisive in the entire treatment pathway. With the popularity of molecular subtyping in clinical practice, erdafitinib is changing the treatment landscape of advanced bladder cancer and promoting innovation in the management of genetic mutation-driven tumors.

References：https://www.balversa.com/